COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Chang, C. W. [1 ]
Lang, H. C. [1 ]
机构：
[1] Natl Yang Ming Univ, Taipei, TPE, Taiwan
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.696
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG17
引用
收藏
页码：S165 / S166
页数：3
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [2] Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
    Ondhia, Umang
    Conter, H. J.
    Owen, Scott
    Zhou, Anna
    Nam, Julian
    Singh, Sumeet
    Abdulla, Ahmed
    Chu, Paula
    Felizzi, Federico
    Paracha, Noman
    Sanghag, Randeep
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (07) : 625 - 637
  • [3] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [4] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [5] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    [J]. PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [6] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    [J]. PharmacoEconomics, 2004, 22 : 581 - 589
  • [7] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [8] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [9] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [10] COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA
    Alhammad, A.
    Lecca, Garrido S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A741 - A741
12345